European Union

Humira patent thicketing strategy not anticompetitive, court rules

Antitrust doctrine not “proper fix” for any problems at the USPTO or FDA, says Illinois judge

Humira patent thicketing strategy not anticompetitive, court rules
Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences
12 Jun 2020

Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences

The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players

EPO plant patent change after president’s intervention raises major concerns
19 May 2020

EPO plant patent change after president’s intervention raises major concerns

The enlarged board’s decision that plants produced by biological processes are unpatentable has shocked the IP profession and came after office head António Campinos asked it to look again at previous ruling

Latest

View all
12 May 2020

Six key takeaways from the CJEU’s latest SPC ruling

Royalty Pharma decision answers important questions about Article 3(a) of the EU’s patent extension rights regulation, but creates new uncertainties Read more

9 Apr 2020

World leaders hatch further plans for accessibility of covid-19 IP rights

WHO to establish voluntary patent pool, while Greek Prime Minister calls for EU to buy rights to vaccines and tests Read more

2 Apr 2020

Patent opportunities and dangers in the microbiome revolution

It is a key part of our growth strategy and we actively seek to ensure IP strategies are in place to protect our investment, says senior DuPont counsel Read more

24 Mar 2020

Covid-19 emergency may expose compulsory licensing limits

Government responses to the pandemic could include increased focus on obligatory sharing of patented inventions, but regulatory data exclusivities might serve as a barrier in both Europe and the United States. Read more

Designs

View all
18 Dec 2019

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

25 Sep 2019

Copyright clarification from Europe’s top court

Judges at the Court of Justice of the European Union delivered good news for designers in their Cofomel decision earlier this month Read more

3 Jul 2019

Law firm’s patent attorney deal shows changing face of IP practice in the UK

Lewis Silkin’s acquisition of Ablett & Stebbing is a first and demonstrates just how far things have moved in a once conservative market Read more

12 Oct 2017

Effective use of Community design protection

Design protection has taken on an increasingly important role in recent years, since appearance and exterior shape now play a fundamental role in the success of a product. Designs are now relevant to a wide range of products involving industry,… Read more

Finance

View all
22 Jun 2018

Qualcomm, France Brevets and IP Europe join forces to create a new funding initiative for European SMEs

A new financing and advisory mechanism to help innovative European SMEs secure high-quality patents and build effective portfolios will be rolled out across Europe in 2019, it was revealed today. The creation of Patent Factory Europe (PFE) was…

Read more

30 Aug 2016

Europe’s multi-billion dollar tax ruling against Apple throws treatment of IP assets into spotlight

The announcement today by the European Commission that Ireland must claw back €13 billion in tax revenues from Apple looks set to escalate the back and forth on the tax practices of major multinationals who use their economic leverage to benefit…

Read more

1 Aug 2016

The European patent market – where should investors look next?

A growing number of patent owners in the European Union probably have the potential to monetise their patents – but do they know the best way to go about this?

Read more

7 Jun 2016

Google shake-up; SMEs 4 the UPC; Europe warning; China insights and more from IPBC Global 2016 Day Two

All the plenary and breakout sessions have now come to an end at IPBC Global 2016. It’s been one hell of an event. IAM’s editorial team on the ground in Barcelona – editor Joff Wild (JW); North America editor Richard Lloyd (RL); Asia editor Jacob…

Read more

Frand/SEPS

View all
12 Jun 2019

Group including Ericsson Nokia, InterDigital and Qualcomm releases SEP licence negotiation principles

Move designed to influence debate in Europe and comes on same day as implementers publish their own guidelines. Read more

14 May 2019

Why it's time for Europe to move beyond 5G's tired developers v implementers patent narrative

With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more

3 Apr 2019

IAM’s Auto IP series taking place against a backdrop of major change

With so many issues emerging across the entire supply chain, the sector’s IP leaders will be sharing their thoughts and insights at events in Detroit and Munich next month Read more

9 Nov 2018

SEP owners must beware of hindering Europe's golden 5G opportunity

In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive Read more

Law & Policy

View all
12 Mar 2020

2020: A Busy Year for CRISPR Patents at the EPO

Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more

6 Mar 2020

Exclusive to IAM, the EPO president's first in-depth interview since getting the job

After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more

3 Mar 2020

A UPC without the UK adds to life sciences concerns about the court

Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more

26 Feb 2020

CJEU for the first time considers the lawfulness (or otherwise) of pay-for-delay patent settlements

Pharmaceutical manufacturers may now find that authorities across Europe increasingly scrutinise patent litigation settlements Read more

Litigation

View all
12 Mar 2020

2020: A Busy Year for CRISPR Patents at the EPO

Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more

6 Mar 2020

Exclusive to IAM, the EPO president's first in-depth interview since getting the job

After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more

3 Mar 2020

A UPC without the UK adds to life sciences concerns about the court

Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more

26 Feb 2020

CJEU for the first time considers the lawfulness (or otherwise) of pay-for-delay patent settlements

Pharmaceutical manufacturers may now find that authorities across Europe increasingly scrutinise patent litigation settlements Read more

Market Developments

View all
12 Mar 2020

2020: A Busy Year for CRISPR Patents at the EPO

Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more

3 Mar 2020

A UPC without the UK adds to life sciences concerns about the court

Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more

6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

4 Feb 2020

Pharma companies need data strategies more than ever following recent CJEU decisions

Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more

Non-Practising Entities

View all
6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

15 Jan 2020

Updated: Broad Institute faces tough fight in CRISPR patent appeal hearing

Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape Read more

14 Nov 2019

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

12 Nov 2019

US government patent suit against Gilead could be a sign of things to come

After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016 Read more

Patent Pools

View all
14 May 2019

Why it's time for Europe to move beyond 5G's tired developers v implementers patent narrative

With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more

9 Nov 2018

SEP owners must beware of hindering Europe's golden 5G opportunity

In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive Read more

Patents Law

View all
12 Mar 2020

2020: A Busy Year for CRISPR Patents at the EPO

Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more

6 Mar 2020

Exclusive to IAM, the EPO president's first in-depth interview since getting the job

After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more

3 Mar 2020

A UPC without the UK adds to life sciences concerns about the court

Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more

26 Feb 2020

CJEU for the first time considers the lawfulness (or otherwise) of pay-for-delay patent settlements

Pharmaceutical manufacturers may now find that authorities across Europe increasingly scrutinise patent litigation settlements Read more

Strategy

View all
12 Mar 2020

2020: A Busy Year for CRISPR Patents at the EPO

Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more

3 Mar 2020

A UPC without the UK adds to life sciences concerns about the court

Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more

26 Feb 2020

CJEU for the first time considers the lawfulness (or otherwise) of pay-for-delay patent settlements

Pharmaceutical manufacturers may now find that authorities across Europe increasingly scrutinise patent litigation settlements Read more

6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

Technology Licensing

View all
6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

16 Jan 2020

Breaking: EPO Board of Appeal upholds invalidation of Broad’s CRISPR-Cas9 patent

Surprise move means Enlarged Board will not now be asked to consider key questions that were referred to it yesterday Read more

15 Jan 2020

Updated: Broad Institute faces tough fight in CRISPR patent appeal hearing

Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape Read more

4 Dec 2019

What leaked US trade talks tell us about future of UK pharma IP

Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month Read more

Trade Secrets

View all
6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

4 Feb 2020

Pharma companies need data strategies more than ever following recent CJEU decisions

Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more

18 Dec 2019

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

14 Nov 2019

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

Valuation

View all
6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

4 Feb 2020

Pharma companies need data strategies more than ever following recent CJEU decisions

Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more

14 Nov 2019

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

8 Nov 2019

Catch up on the most important life sciences IP developments from the past month

Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019 Read more

Find an expert

David Divine
Partner
Spokane WA, United States
Lee & Hayes, PC